| 2026-08-07 | Deck | CytomX Therapeutics Corporate Presentation – August 2026 |
| 2026-08-06 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-06 | Press release | PDF Version |
| 2026-08-06 | Press release | CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-03 | Press release | PDF Version |
| 2026-08-03 | Press release | CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer |
| 2026-07-30 | Press release | PDF Version |
| 2026-07-30 | Press release | CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-27 | Press release | PDF Version |
| 2026-07-27 | Press release | CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors |
| 2026-07-27 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-22 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-03 | Press release | PDF Version |
| 2026-06-03 | Press release | CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific The |
| 2026-06-03 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-21 | Press release | PDF Version |
| 2026-05-21 | Press release | CytomX Therapeutics to Present at Upcoming June Investor Conferences |
| 2026-05-18 | Press release | PDF Version |
| 2026-05-18 | Press release | CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs |
| 2026-05-07 | Press release | PDF Version |
| 2026-05-07 | Press release | CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Press release | PDF Version |
| 2026-04-30 | Press release | CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-03-19 | 8-K | Form 8-K, Item 8.01 |
| 2026-03-17 | Press release | PDF Version |
| 2026-03-17 | Press release | CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants |
| 2026-03-16 | Press release | CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update |
| 2026-03-16 | Press release | PDF Version |
| 2026-03-16 | Press release | PDF Version |
| 2026-03-16 | Press release | PDF Version |
| 2026-03-16 | Press release | CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 2026-03-16 | Press release | CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New |
| 2026-03-16 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-16 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-04 | Press release | PDF Version |